
## Jeremy S Setton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2520741/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<i>ATM</i> Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications. Journal of the National Cancer Institute, 2022, 114, 761-770.	6.3	3
2	Pathogenic <i>ATM</i> Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. Journal of the National Cancer Institute, 2021, 113, 266-273.	6.3	38
3	Homologous recombination deficiency: how genomic signatures are generated. Current Opinion in Genetics and Development, 2021, 66, 93-100.	3.3	13
4	Synthetic Lethality in Cancer Therapeutics: The Next Generation. Cancer Discovery, 2021, 11, 1626-1635.	9.4	91
5	Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination. Npj Breast Cancer, 2021, 7, 135.	5.2	9
6	Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs. Cell, 2020, 183, 197-210.e32.	28.9	141
7	Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. Nature Cancer, 2020, 1, 1188-1203.	13.2	114
8	Moving beyond PARP Inhibition in ATM-Deficient Prostate Cancer. Cancer Research, 2020, 80, 2085-2086.	0.9	3
9	The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers. JNCI Cancer Spectrum, 2019, 3, pkz027.	2.9	20
10	A new role for a tumor-suppressing protein. ELife, 2018, 7, .	6.0	0
11	The therapeutic significance of mutational signatures from DNA repair deficiency in cancer. Nature Communications, 2018, 9, 3292.	12.8	153
12	Patterns of nodal failure after intensity modulated radiotherapy for nasopharyngeal carcinoma. Laryngoscope, 2017, 127, 377-382.	2.0	16
13	Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in <i>ATM</i> . Oncotarget, 2017, 8, 10312-10323.	1.8	31
14	Long-term patterns of relapse and survival following definitive intensity-modulated radiotherapy for non-endemic nasopharyngeal carcinoma. Oral Oncology, 2016, 53, 67-73.	1.5	44
15	Dose-volume factors correlating with trismus following chemoradiation for head and neck cancer. Acta Oncológica, 2016, 55, 99-104.	1.8	36
16	A multiâ€institution pooled analysis of gastrostomy tube dependence in patients with oropharyngeal cancer treated with definitive intensityâ€modulated radiotherapy. Cancer, 2015, 121, 294-301.	4.1	109
17	Estimate of the impact of FDG-avidity on the dose required for head and neck radiotherapy local control. Radiotherapy and Oncology, 2014, 111, 340-347.	0.6	38
18	The relative prognostic utility of standardized uptake value, gross tumor volume, and metabolic tumor volume in oropharyngeal cancer patients treated with platinum based concurrent chemoradiation with a pre-treatment [18F] fluorodeoxyglucose positron emission tomography scan. Oral Oncology, 2014, 50, 802-808.	1.5	34

JEREMY S SETTON

#	Article	IF	CITATIONS
19	Patients with low lying lymph nodes are at high risk for distant metastasis in oropharyngeal cancer. Oral Oncology, 2014, 50, 863-868.	1.5	20
20	Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC). Oral Oncology, 2014, 50, 947-955.	1.5	51
21	Intensity-Modulated Radiotherapy in the Treatment of Oropharyngeal Cancer: An Update of the Memorial Sloan-Kettering Cancer Center Experience. International Journal of Radiation Oncology Biology Physics, 2012, 82, 291-298.	0.8	168
22	Definitive treatment of metastatic nasopharyngeal carcinoma: Report of 5 cases with review of literature. Head and Neck, 2012, 34, 753-757.	2.0	41
23	Radiation field design and regional control in sentinel lymph nodeâ€positive breast cancer patients with omission of axillary dissection. Cancer, 2012, 118, 1994-2003.	4.1	25
24	Melanoma metastatic to multiple visceral organs: further considerations. Oncology, 2010, 24, 654-5.	0.5	0